ImmunoGen, Inc. Earns Milestone With Start of SAR3419 Phase II Testing
October 20, 2011 06:20 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Oct. 20, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
ImmunoGen, Inc. Announces Webcast of Presentation at the 18th Annual NewsMakers in the Biotech Industry Conference
October 13, 2011 06:01 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Oct. 13, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its...
T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
September 24, 2011 18:02 ET
|
ImmunoGen, Inc.
Notable results from Genentech/Roche Phase II trial are featured in conference's official press program
T-DM1 utilizes ImmunoGen's Targeted Antibody Payload (TAP) technology with the...
ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma
September 22, 2011 16:01 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Sept. 22, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
August 31, 2011 06:31 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Aug. 31, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and...